Viridian Therapeutics Inc
Change company Symbol lookup
Select an option...
VRDN Viridian Therapeutics Inc
DD Dupont De Nemours Inc
NRXPW NRX Pharmaceuticals Equity Warrant Exp 24 May 2026 *W EXP 05/24/2026
SAH Sonic Automotive Inc
PCRX Pacira Biosciences Inc
ONFO Onfolio Holdings Inc
LSPRU Larkspur Health Acquisition Corp
BKKT Bakkt Holdings Inc
PDI PIMCO Dynamic Income Fund
RNR Renaissancere Holdings Ltd
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Viridian Therapeutics, Inc. is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company is engaged in developing two product candidates, VRDN-001 and VRDN-002, to treat patients who suffer from thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED.

Closing Price
$22.61
Day's Change
-0.20 (-0.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
23.31
Day's Low
22.31
Volume
(Light)
Volume:
271,994

10-day average volume:
463,773
271,994
Latest Earnings Beat Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 14, 2022
-$0.86Q3 Consensus
of 8 analysts
-$1.02Difference from
consensus
15.44%
Q4 Earnings
will announce
(Unconfirmed) March 8, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

VRDN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.